News & Updates

Parathyroidectomy does not lessen morbidity, mortality in mild hyperparathyroidism
Parathyroidectomy does not lessen morbidity, mortality in mild hyperparathyroidism
29 Apr 2022

Parathyroidectomy (PTX) seems ineffective at reducing morbidity or mortality in patients with mild primary hyperparathyroidism (PHPT) relative to observation without intervention, suggests a study. For at least a decade, observation has seen no evidence of adverse effects regarding mortality, fractures, cancer, cardiovascular (CV) and cerebrovascular (CBV) events, or renal morbidities.

Parathyroidectomy does not lessen morbidity, mortality in mild hyperparathyroidism
29 Apr 2022
Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer
Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer
29 Apr 2022 byAudrey Abella

In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.

Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer
29 Apr 2022